Company Monitoring Page for Keryx

latest headlines for company on cafepharma

Zalicus May Be 2012's 'Come Back Kid' Biotech Stock
Seeking Alpha
Thu, 03/8/12 - 10:00 am
Tags:
Zalicus, Z160, Keryx, Aeterna Zentaris
The Other Side Of Keryx And AEterna
Seeking Alpha
Wed, 03/7/12 - 10:08 am
Tags:
Keryx, Aeterna Zentaris, perifosine
AEterna, Keryx soar on study speculation
Marketwatch
Mon, 03/5/12 - 06:16 pm
Tags:
Keryx, Aeterna Zentaris, perifosine, colorectal cancer, Multiple Myeloma
FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris
Seeking Alpha
Sat, 03/3/12 - 11:20 am
Tags:
Keryx, Aeterna Zentaris, perifosine
3 Biotech Companies: 2 To Buy And 1 To Day Trade
Seeking Alpha
Tue, 02/28/12 - 10:10 am
Tags:
Avanir, Spectrum Pharmaceuticals, Keryx, Aeterna Zentaris
Buy, Sell, or Hold: Keryx Pharmaceuticals
Motley Fool
Fri, 02/24/12 - 09:56 am
Tags:
Keryx, colorectal cancer, Zerenex, perifosine, kidney failure
Biotech Stock Mailbag: Vivus, Chelsea, BioCryst
TheStreet.com
Fri, 02/17/12 - 09:05 am
Tags:
Vivus, Chelsea Therapeutics, Keryx, Biocryst, Exelixis, BioSante
5 High-Risk, High-Reward Biopharma Stocks
Seeking Alpha
Tue, 02/14/12 - 11:30 am
Tags:
Arena Pharmaceuticals, Chelsea Therapeutics, BioLineRx, Keryx, Aeterna Zentaris
BIO CEO Confab Live Blog: Day 2
TheStreet.com
Tue, 02/14/12 - 11:29 am
Tags:
BIO CEO Conference, Pfizer, Indenix, Keryx, Delcath, Oncothyreon, Acorda Therapeutics, Human Genome Sciences, Gilead
The Best Biotech Stocks Of 2012
Seeking Alpha
Mon, 01/23/12 - 02:19 pm
Tags:
Advanced Cell Technologies, Aeterna Zentaris, Antares, BioSante, Geron, Hikma, Keryx, Pfizer, Sanofi, Teva Pharmaceuticals, Transcept, Yakult Honsha, Watson Pharmaceuticals
Biopharma Stocks To Watch This Week
Seeking Alpha
Thu, 01/19/12 - 11:12 am
Tags:
BioDelivery Sciences, Biovest International, Celldex, MannKind, NovaBay Pharmaceuticals, Keryx, ImmunoCellular, Cel-Sci, Dendreon, Generex, Human Genome Sciences
2 High-Flying Biotechs Face a New Hurdle
Motley Fool
Thu, 01/19/12 - 10:57 am
Tags:
Bayer, ONYX Pharmaceuticals, Aeterna Zentaris, regorafenib, Keryx
11 Biotech Bets For 2012
Seeking Alpha
Thu, 01/12/12 - 10:16 pm
Tags:
Zalicus, Teva Pharmaceuticals, Spectrum, Astex, Aeterna Zentaris, Cel-Sci, Dendreon, Keryx, NPS Pharmaceuticals, Pharmacyclics, Questcor
KERX Perifosine Analysis
Motley Fool
Thu, 01/12/12 - 09:09 am
Tags:
Keryx, perifosine
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
Wed, 01/4/12 - 10:22 am
Tags:
Celgene, Vivus, Dendreon, Gilead, Incyte, YM BioSciences, ONYX Pharmaceuticals, Seattle Genetics, Vertex, Amarin, Biomarin, Biogen Idec, Regeneron, Merck KGaA, Human Genome Sciences, Clovis Oncology, Roche, Ariad, Immunogen, Medivation, Geron, InterMune, Indenix, Amag Pharmaceuticals, Mesoblast, Arena, MannKind, Keryx, Spectrum Pharmaceuticals
3 Biotechs Hopefully To Get Rich Or Die Trying
Seeking Alpha
Wed, 01/4/12 - 09:28 am
Tags:
Advanced Cell Technologies, Aeterna Zentaris, BioSante, Dendreon, Keryx
What to Look For From Keryx and Aeterna Zentaris in 2012
Motley Fool
Thu, 12/29/11 - 10:32 pm
Tags:
Keryx, Aeterna Zentaris, colon cancer, perifosine
Biotech Stock Mailbag: Most Important Events for 2012
TheStreet.com
Fri, 12/23/11 - 08:56 am
Tags:
Oncothyreon, Keryx, Vical, Aeterna Zentaris, Eli Lilly, JNJ, Elan, Celgene, Pfizer, Gilead, Pharmasset, Threshold Pharmaceuticals, Celldex, Amgen, BioVex, Aveo Pharmaceutical, Amylin, Alkermes, Vertex, Cell Therapeutics, Amarin, ONYX Pharmaceuticals, Vivus
Why Perifosine Phase 3 Trials Will Likely Fail
Seeking Alpha
Thu, 12/8/11 - 11:26 am
Tags:
perifosine, Keryx, Aeterna Zentaris, colon cancer
New Drug Approvals Make Or Break Biotechnology Stocks
Seeking Alpha
Wed, 11/30/11 - 10:46 am
Tags:
Antares, Achillion, Pharmasset, Indenix, Inhibitex, ONYX Pharmaceuticals, Keryx

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.